Abstract Altered cadherin expression is important for metastasis in many carcinomas including head and neck squamous cell carcinoma (SCC). We evaluated E-and N-cadherin expression specifically in oropharyngeal SCC and correlated this with clinical and pathologic features. Oropharyngeal SCC patients with clinical follow up information were identified from clinician databases from 1996 through 2007 and tissue microarrays created. Tumors had been previously typed histopathologically as keratinizing, non-keratinizing, or non-keratinizing with maturation, and had known p16 and human papillomavirus status, respectively. Immunohistochemistry was performed on the microarrays, and staining was evaluated for presence and intensity (0 = negative, 1 = weak, 2 = moderate, 3 = strong) both visually and also with digital image analysis software. Of 154 cases, E-cadherin was expressed in 152 (98.7%) and N-cadherin in 17 (11.5%). Neither E-nor N-cadherin expression was statistically significantly associated with histopathologic type (P = 0.082 and P = 0.228, respectively). E-cadherin staining intensity was not statistically significantly associated with nodal or distant metastasis, either visually or by image analysis, (P = 0.098 and P = 0.963 respectively) nor was N-cadherin (P = 0.228 and P = 0.935 respectively). Neither Enor N-cadherin expression was associated with death from disease (P = 0.995; P = 0.964, respectively). E-cadherin is extensively expressed by oropharyngeal SCC, even the non-keratinizing type. Our results suggest that cadherin expression may not be a predictor for nodal or distant metastasis in these tumors. Mechanisms independent of cadherin expression may be important for metastases in oropharyngeal SCC.
Introduction
Squamous cell carcinoma (SCC) is the most common malignancy of the head and neck. Oropharyngeal SCC, in particular, is increasing in incidence and has unique patient demographics and better outcome [1] [2] [3] . Non-keratinizing oropharyngeal SCC (NK-SCC), in particular, is a subtype of oropharyngeal SCC that is strongly associated with human papillomavirus (HPV) [1] [2] [3] and strong p16 expression [4] [5] [6] and which has a marked propensity for early nodal metastasis. A significant minority of patients with NK-SCC are non-smokers and don't consume significant alcohol [2, 7] . Patients with oropharyngeal SCC also have better survival than non-oropharyngeal SCC patients [2, 3, 7] . Survival is better despite these tumors having the usual poor prognostic factors of nodal metastasis and a so-called ''poorly differentiated'' morphology [1, 3, 8] .
Cadherins are calcium-dependent transmembrane proteins important for cell to cell adhesion through homotypic interactions. Evidence suggests that cadherins are some of the most important adhesion molecules because the inactivation of other cell adhesion molecules typically does not lead to invasive or metastatic phenotypes when cadherins are normally expressed [9] . Several studies have demonstrated that in carcinomas, loss of E-cadherin function is associated with invasion, metastasis, high tumor grade, and increased mortality [10] [11] [12] [13] [14] [15] [16] . Studies have also shown that cadherins have a direct role in nodal and distant metastasis in head and neck squamous cell carcinomas (HNSCC) [8, [17] [18] [19] . Decreased E-cadherin and increased N-cadherin expression in HNSCC have been associated with an increased incidence of nodal and distant metastasis [18] . Most of these studies have combined numerous different anatomic subsites including larynx, hypopharynx, oropharynx, and oral cavity. Cadherin expression specifically in oropharyngeal SCC (and more specifically in NK-SCC) has been little investigated and rarely done so in combination with HPV/p16 stratification. We sought to assess E-and N-cadherin expression by immunohistochemistry in oropharyngeal SCC and to correlate expression with nodal and distant metastasis and with clinical and pathologic features.
Materials and Methods
After approval by the Human Research Protection Office, cases of oropharyngeal SCC from the databases of Radiation Oncology (WLT) and Otolaryngology Head and Neck Surgery were identified. Clinical follow up information was obtained. For our study, cases were considered oropharyngeal if they were clinically centered in the palatine tonsils, base of tongue, lateral or posterior oropharyngeal wall, or soft palate/uvula. We specifically excluded any tumors thought to be clinically centered in the oral cavity or larynx (i.e. involving the anterior tonsillar pillar or retromolar trigone or those tumors of the laryngeal surface of the epiglottis) even if they had oropharyngeal extension clinically. Tumors were typed histopathologically by one study pathologist (JSL) on whole sections according to our previously described classification system [6] as: keratinizing (Type 1), nonkeratinizing (Type 3), and nonkeratinizing with maturation (Type 2). A tissue microarray (TMA) was constructed. According to the amount of available biopsied or resected tumor tissue, duplicate 2 mm (or if insufficient tumor tissue present, then 0.6 mm) punches were taken from each case. Since most of the cases (75%) were treated with primary surgery, the majority of cases on the array had the larger (2 mm) punches.
In Situ Hybridization for HPV
In situ hybridization (ISH) was performed on formalin fixed, paraffin embedded, 4-lm whole tumor sections cut from formalin-fixed, paraffin-embedded tissue blocks from each case using ISH I View Blue Plus Detection Kit (Ventana Medical System, Inc., Tucson, AZ) according to the manufacturer's instructions. The assay utilized the Ventana HPV III Family 16, Probe B, a cocktail recognizing the high risk HPV (HR HPV) types 16, 18, 31, 33, 35, 45 , 51, 52, 56, 58, 59, 68, and 70. Ventana Red Counterstain II (Ventana Medical System, Inc., Tucson, AZ) was used. Cases were read by one study pathologist (JSL). Any definitive blue staining in the tumor cell nuclei was considered positive.
Immunohistochemistry
Immunohistochemistry was performed for p16 on 4 lm whole tumor sections cut from formalin-fixed, paraffinembedded tissue blocks from each case using a monoclonal antibody to p16 (MTM Laboratories; clone E6H4; monoclonal; 1:1 dilution) on a Ventana Benchmark automated immunostainer (Ventana Medical Systems, Inc., Tucson AZ) according to standard protocols with appropriate positive controls. Detection involved Ventana's ultraView Universal DAB Detection Kit which utilizes a cocktail of enzyme labeled secondary antibodies that locate the bound primary antibody. The complex is then visualized with hydrogen peroxide substrate and a 3,3 0 -diaminobenzidine tetrahydrochloride (DAB) chromogen. No biotin is involved. Antigen retrieval, standard on the machine, utilized the Ventana CC1, EDTA-Tris, pH 8.0 solution. Staining was read by one study pathologist (JSL) and all positive cases demonstrated both nuclear and cytoplasmic staining. Cases were classified in quartiles by percentage of cells with positive nuclear and cytoplasmic staining as follows: 0 = no staining; 1? = 1-25%; 2? = 26-50%; 3? = 51-75%; 4? = 76-100%. Since it is generally accepted that only high expression of p16 correlates with biologically active HPV in oropharyngeal SCC, we classified tumors as ''positive'' if they had 3? or 4? staining and all others as ''negative''.
Immunohistochemistry was performed by hand on 4 lm sections cut from the tissue microarray blocks for E-cadherin (Dako; clone NCH-38; monoclonal; dilution 1:200; antigen retrieval: EDTA buffer pH 8.0 with heat induced epitope retrieval using 3 min in a pressure cooker) and N-cadherin (Invitrogen; clone 3B9; monoclonal; dilution 1:200; antigen retrieval: citrate buffer pH 6.0 with heat induced epitope retrieval utilizing 3 min in a pressure cooker). Staining was detected using a MACH 4 secondary (Biocare Medical, Concord, CA) which involves a chromogenic reaction with a horseradish peroxidase polymer which binds to the secondary antibody. We utilized separate sections of normal pancreas as positive controls, which show moderate membranous staining of the acinar cells for both E-and N-cadherin. In addition, normal liver tissue, present on most array blocks (as punches to spatially orient the arrays), showed moderate, diffuse, membranous staining for both E-and N-cadherin and thus served as an internal positive control. Negative controls, omitting the primary cadherin antibodies and including mixture of mouse immunoglobulins, were performed with both staining runs.
The cadherin immunostained slides were digitally scanned (Aperio ScanScope XT digital scanner) at 4009 magnification and then reviewed on a computer screen by one study pathologist (OCU), and staining (intensity score) graded visually as follows: circumferential membranous staining, weak = 1, moderate = 2, strong = 3. No distribution score was applied for E-cadherin because all positive cases had a diffuse expression pattern. No distribution score was applied for N-cadherin because all positive cases had focal, patchy expression. Cases with less than 10% surface area of tumor present (over the surface of both microarray cores) were excluded for having insufficient tumor present for reliable determination of tumor staining. All stains were reviewed by the pathologists in a blinded manner to clinical/ outcome information.
In addition, since the E-cadherin stains were almost all extensively positive, an attempt to better quantify and characterize the immunohistochemical staining was made by performing software-based digital image analysis. The digitally scanned slides were segmented using the Aperio TMA Laboratory microarray analysis tool, and then all cases were analyzed using the Membrane Quantification Tool, version 9 (part of the Aperio Image Analysis Toolbox). This provided both a simple, continuous, average intensity score, and also featured a pre-designed Her2neu membrane analysis algorithm, which yielded scores between 0 and 3 (Aperio Technologies, Inc., Vista, CA). The software recognizes membranous, brown staining in the cells and, based on intensity score, uses specific thresholds for the cells. The ''out of the box'' settings for the Membrane Quantification Tool Version 9 algorithm were utilized without modification. Hereafter, cadherin readings are referred to as ''visual'' for pathologist visual readings and those readings by digital image analysis are referred to as ''digital.''
Statistics
Categorical data were presented with frequency and percentage, while continuous variables were described with mean and standard deviation. To evaluate the association between any two categorical data, we used Pearson's Chisquare Test or Fisher's Exact Test when proper. The duration of follow up was considered as the date of treatment start (either surgical resection or beginning of radiation therapy) to the last follow up date or death. Survival probability was evaluated with Kaplan-Meier method. The impacts of individual risk factors to survival likelihood were examined by Log-Rank test. Patients dying with clinical evidence of disease were considered as dying of this disease rather than of other causes. When testing the influence of E-cadherin and N-cadherin expression, these variables were classified by their visual intensity scores. For E-cadherin, digital membrane intensity scores were analyzed as a continuous variable to outcomes using logistic regression. E-cadherin scores by the Her2 digital image analysis were compared to visual scoring with agreement assessed by kappa statistical analysis. All P values were two sided with P values \ 0.05 considered statistically significant. All the major statistical calculation was performed in SAS 9.1 (SAS institute, Cary, NC).
Results
Overall patient demographics and those stratified by cadherin intensity scores are presented in Fig. 2 ) was present in 17 (11.5%) of the cases (no staining: 87.1%; weak: 9.5%; moderate: 2%; and strong: 0%). Neither E-nor N-cadherin expression was statistically significantly associated with histopathologic type (P = 0.08, and P = 0.22, respectively; Figs. 3, 4) although there was a slight trend towards moderate intensity staining for E-cadherin in NK-SCC. E-and N-cadherin visual intensity scores were independent of each other (P = 0.793). 6 (37.6) 0 (0) Other P = 0.262* P = 0.641** IMRT intensity modulated radiation therapy, SCC squamous cell carcinoma, NK nonkeratinizing, K keratinizing, SD standard deviation *P value for univariate analysis of E-cadherin score with respective variable ** P value for univariate analysis of N-cadherin score with respective variablê
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Specifically, we did not observe a trend towards presence of N-cadherin expression in tumors which had reduced E-cadherin intensity scores (2 or 1) or that were E-cadherin negative. E-cadherin intensity score assessed visually was not correlated with nodal metastasis (P = 0.830, Table 1 ) or with distant metastasis (P = 1.00, Table 1 ). N-cadherin was not associated with nodal or distant metastases, either (P = 0.150 and P = 0.560, respectively, Table 1 ). E-cadherin expression loss was associated with HPV status by in situ hybridization (P = 0.037), but N-cadherin expression was not (P = 1.00, Table 2 ). E-and N-cadherin intensity scores were not associated with p16 expression (P = 0.58 and 1.00 respectively, Table 2 ), either. Amongst the cohort of 41 patients with keratinizing-type SCC (Type 1) which were p16 negative (or had weak expression with less than 50% of the tumor cells staining), we still found no correlation of E-cadherin expression with nodal (P = 0.90) or distant metastasis (P = 0.48).
The mean and median follow-up for surviving patients were 3.29 and 2.74 years, respectively (range 0.1-12.35 years). In follow-up, neither E-nor N-cadherin expression assessed visually was associated with death from disease (P = 0.99 and P = 0.96, respectively), and neither E-nor N-cadherin expression was predictive of overall (P = 0.56 and P = 0.63, respectively) or disease free survival (Figs. 5, 6 ).
Digital image analysis was also performed, as previously described, on the E-cadherin slides. When compared to the visual results, the Her2 software algorithm results showed significant disagreement (j = 0.08), with most cases visually graded as 2? being classified as 3? by the software (Table 3 ). The digital analysis also provided membrane intensity scores as continuous results between 73 and 165, and these did not correlate well with visual E-cadherin scores (R 2 = 0.01, Table 4 ), either. Analyzed on their own as a continuous variable, E-cadherin membrane intensity scores assessed digitally also were not associated with nodal metastasis (P = 0.65) or overall or disease-specific survival (P = 0.34 and P = 0.28, respectively). E-cadherin scores assessed digitally with the Her2 software algorithm were also not associated with nodal metastasis (P = 0.98) or overall or disease specific survival (P = 0.93 and P = 0.78, respectively).
Discussion
As there is emerging recognition of the unique biology of oropharyngeal SCC relative to other head and neck SCC [7, 20], we investigated cadherin expression in a large cohort of oropharyngeal SCC with known HPV and p16 status. Our results suggest that cadherin expression in oropharyngeal SCC is not associated with nodal or distant metastasis, or at least not in a way that significantly lessens E-cadherin expression or increases N-cadherin expression, as detected by immunohistochemistry. Since keratinizingtype SCC is more frequently associated with larger primary tumors and less frequently with nodal metastases at presentation and NK-SCC more frequently has smaller primary tumors with early and frequent nodal metastasis [6] , one might have predicted that E-cadherin expression in these latter tumors would be decreased or possibly absent relative to the former. What we found is that there was consistent and diffuse expression of E-cadherin across all three histologic types with 96% of K-SCC, 92.9% of NK-SCC, and 90% of NK-SCC with maturation showing strong (2? or 3? in intensity) membranous staining.
Some previous studies of head and neck SCC have shown that loss of E-cadherin expression with a concomitant increase in N-cadherin expression is associated with nodal metastasis [21, 22] . One large study, which included numerous different head and neck subsites, demonstrated that a loss of E-cadherin expression is correlated with N-cadherin score 2 3 1 3 1 *P = 1.00 **P = 1.00
HPV human papillomavirus, ISH in situ hybridization * P value correlating E-cadherin score to HPV ISH result ** P value correlating E-cadherin score to p16 result Fig. 5 There was no correlation between E-cadherin staining intensity by visual analysis and overall survival (P = 0.56) Fig. 6 There was no correlation between N-cadherin expression and overall survival (P = 0.62) 0  0  2  2  0  3  7  3  1 3   3  0  3  6 5  6 8  1 3 6   Total  2  7  72  71  152 poorly differentiated tumors, lymph node metastasis, and poor survival [23, 24] . They stained whole tissue sections and graded E-cadherin on loss of staining relative to strength of staining in normal squamous mucosa controls. In particular, they report variation of staining strength within the tumors. We examined TMA cores rather than whole tumor sections. However, since 75% of our cases had duplicate 2 mm cores, we did have relatively generous amounts of tumor to examine for a TMA-based study. We did not find any significant variation in the presence or intensity of staining in our cases. We found the membranous expression to be consistent across the tumor cells. We further utilized digital image analysis software to characterize the intensity of staining of the E-cadherin cases, since the human eye is not well-suited for quantitation. The digital membrane intensity scores and the quantitation algorithm designed for Her2neu membrane staining analysis did not correlate well with the visual analysis (Tables 3, 4) . Nonetheless, there was no correlation with metastasis or patient outcomes utilizing these results, either.
The only specific association that we found was between HPV ISH positivity and decreased (Score 0-2) E-cadherin expression (P = 0.038). For p16 IHC, however, we did not find a statistically significant correlation (P = 0.58). This could be a reflection of HPV E6/E7 proteins alterating beta-catenin/E-cadherin as has been reported in some studies [25] . N-cadherin expression was relatively rare in our cohort with only 16 (10.5%) of the specimens showing staining. We found no correlation with metastasis or patient survival. As previously mentioned, prior studies have indicated that aggressiveness in head and neck SCC is related to inverse cadherin expression with decreased E-cadherin expression and a concomitant increase in N-cadherin expression. In our cohort, there was no association between expression of these two (P = 0.635).
The cohorts of patients in most of the other studies on cadherin expression are small or, if larger, consist of SCC from a mixture of head and neck subsites, with only two [19, 26] of these studies having more than 35% of cases from the oropharynx [18, 23, 27] . The more focused single site studies looked at oral cavity or laryngeal carcinomas alone [22, 28] . One of the studies that did look specifically at E-cadherin in 57 cases of oropharyngeal SCC [19] found that 82.5% of cases expressed E-cadherin (negative staining was considered no staining or less than 5% staining) and did not find a correlation between lack of expression and metastasis or patient outcome. Their study did not include HPV or p16 status of the tumors. The other oropharyngeal SCC only study, by Stenner et al. [26] , studied whole sections in 96 cases and found that 61% lacked E-cadherin (no staining or \5% staining) and found that p16 positive tumors also frequently lacked E-cadherin staining in their cohort. They correlated loss with metastasis.
Some other studies have also found aberrant nuclear or cytoplasmic localization of E-cadherin [27] . We did not find evidence of this. However, we note that the pattern of E-cadherin staining can vary depending on the tumor and antibody clone used. The clone we used binds to the extracellular domain of E-cadherin and so may not detect aberrant or truncated protein localizing intracellularly.
Why did we not find a correlation between cadherin expression and metastases or outcome in oropharyngeal SCC when many others have found such a correlation in head and neck SCC? With the relationship to HPV, most oropharyngeal SCCs are biologically unique relative to other head and neck sites. Our findings may be a reflection of this biology and seem to indicate that there are other, more important, and potentially novel, mechanisms of metastasis in these tumors. It also may be a reflection of the variability of technical methods in immunohistochemistry, particularly since we utilized the same E-cadherin antibody clone as a recent study by Stenner et al. and got different results. Given the sizeable number of variables in immunohistochemistry, though, it is hard to compare the technical aspects of our staining with the others. However, our staining was specifically clean and strong, even using the exact antibody as others, suggesting that E-cadherin is retained, at least to some degree, in metastasizing SCCs.
A limitation of this study is the enrichment of tumors with nodal metastasis (83.8%) and also the relatively low number with distant metastasis (5.8%), which limits our study's power to detect a relationship with cadherin expression. It is possible that there is more differential expression of cadherins in the group without nodal metastasis, but our current data does not support that hypothesis. We also considered variation of staining patterns that may not be captured in tissue microarray punches. It is possible that a small tissue punch may not be representative of the entire tumor, and hence there can be staining variation that is missed. However, our punch sizes were generous (2 mm in most cases) and were duplicate in all of them. All cases showed, in the positive cases, strong and diffuse staining for both cores which suggests a lack of variation in the tumors. Some have also suggested cadherin loss at the ''leading edge'' of infiltrating tumors as a biological phenomenon in carcinomas. Our punches were not specifically selected for either the center or leading edge of the tumors so it is possible we could be missing ''leading edge cadherin loss'' in the tumors. This could be an explanation for why our findings differ from many others on cadherins in head and neck SCC.
The mere presence of E-cadherin on the cell membrane does not indicate functional status. E-cadherin is a complex molecule with both structural and signaling roles in the cell. The protein p120 is known to bind to and inactivate E-cadherin [29] . If this mechanism is true for oropharyngeal SCC, we could still see strong expression of E-cadherin, albeit nonfunctional. Tyrosine phosphatase inactivation of the E-cadherin/b-catenin complex also inactivates E-cadherin [30, 31] . One might speculate that oropharyngeal SCC may have mediators that play a role in either p120 expression, tyrosine phosphatase inactivation, or other E-cadherin modification or suppression that are independent of actual E-cadherin expression. Future investigations of other cadherin-related pathways in HPVassociated/p16 positive oropharyngeal SCC perhaps would provide further insight.
In summary, we did not find any significant correlation between expression of E-and N-cadherin with clinicopathologic features or patient outcome in a TMA-based cohort of oropharyngeal SCC. Our fundings suggest that other factors besides altered cadherin expression may be important for metastasis in oropharyngeal SCC.
